Trial Profile
A Non-Interventional, Open, Prospective, Multi-centre study study to evaluate the safety and efficacy of Alirocumab in patients with Hypercholesterolaemia in the real-world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2018
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms PEARL
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 19 Sep 2018 New trial record
- 29 Aug 2018 Final results and results in subgroup of patients with CHD or ACS, presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology